mProX™ Human MAP3K19 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAP3K19 is a gene that has been implicated in various diseases and conditions. In the context of congenital heart disease (CHD), a meta-analysis identified MAP3K19 as one of the novel candidate genes associated with CHD. The study found that MAP3K19 was upregulated in cardiomyocytes, suggesting its involvement in CHD pathogenesis. In the context of COVID-19, a study found that MAP3K19 regulatory variation in populations with African ancestry may increase the severity of the disease. The study revealed that a specific genetic variant of MAP3K19 was associated with reduced expression of the gene, which may contribute to the increased risk of severe COVID-19. In ovarian cancer, MAP3K19 was identified as a key target of CC chemokine 2 (CCL2) in promoting cancer progression. Knockout of MAP3K19 inhibited ovarian cancer cell proliferation, migration, and invasion. Additionally, in lung adenocarcinoma, a prognostic risk model based on an oxidative stress-related gene signature included MAP3K19 as one of the genes. The study showed that MAP3K19, along with another gene NTSR1, had clinical significance in identifying prognosis and guiding immunotherapy in lung adenocarcinoma patients. Lastly, in bicuspid aortic valve (BAV) patients, whole-exome sequencing identified MAP3K19 as one of the recurrent variants implicated in the disease. BAV patients carrying MAP3K19 variants showed reduced left ventricular ejection fractions and larger calcification volume, indicating its association with disease severity. Overall, MAP3K19 has been implicated in various diseases and conditions, highlighting its potential as a target for further research and therapeutic interventions.